Sign in

CIK 0001652130 · Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364785571
Phone
857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$417,899
in 3 filings, $395K under 10b5-1 plans

Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. LEONARD JOHN M −$395K President and CEO sold 3% of stake
  2. Dube Michael P −$23K VP, Chief Accounting Officer sold 3% of stake

Reading 7 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2016-05-11 Atlas Venture Fund IX, L.P. 10% owner Conversion +611,827 611,827
2016-05-11 Atlas Venture Fund IX, L.P. 10% owner Conversion +2,463,201 3,075,028
2016-05-11 Atlas Venture Fund IX, L.P. 10% owner Conversion +862,120 3,937,148
2016-05-11 Atlas Venture Fund IX, L.P. 10% owner Conversion +492,640 4,429,788
2016-05-11 Atlas Venture Fund IX, L.P. 10% owner Conversion · Founder Stock −946,237 0
2016-05-11 Atlas Venture Fund IX, L.P. 10% owner Conversion · Series A-1 Preferred Stock −3,809,524 0
2016-05-11 Atlas Venture Fund IX, L.P. 10% owner Conversion · Series A-2 Preferred Stock −1,333,333 0
2016-05-11 Atlas Venture Fund IX, L.P. 10% owner Conversion · Series B Preferred Stock −761,905 0
2016-05-11 Novartis Institutes for BioMedical Research, Inc. 10% owner Conversion +3,079,001 3,079,001
2016-05-11 Novartis Institutes for BioMedical Research, Inc. 10% owner Conversion +1,724,240 4,803,241
2016-05-11 Novartis Institutes for BioMedical Research, Inc. 10% owner Conversion +492,640 5,295,881
2016-05-11 Novartis Institutes for BioMedical Research, Inc. 10% owner Purchase +277,777 $18.00 $5.0M 5,573,658
2016-05-11 Novartis Institutes for BioMedical Research, Inc. 10% owner Conversion · Series A-1 Preferred Stock −4,761,905 0
2016-05-11 Novartis Institutes for BioMedical Research, Inc. 10% owner Conversion · Series A-2 Preferred Stock −2,666,666 0
2016-05-11 Novartis Institutes for BioMedical Research, Inc. 10% owner Conversion · Series B Preferred Stock −761,905 0
2016-05-11 Haurwitz Rachel E. Director Conversion +174,806 349,612
2016-05-11 Haurwitz Rachel E. Director Conversion +5,244,234 5,593,846
2016-05-11 Haurwitz Rachel E. Director Conversion · Founder Stock −270,352 0
2016-05-11 Haurwitz Rachel E. Director Conversion · Junior Preferred Stock −8,110,599 0
2016-05-11 Caribou Therapeutics Holdco, LLC 10% owner Conversion +174,806 349,612

Page 39 of 40 · 783 trades